BPC-157 for Knee, Tendon and Back Pain: The Human Evidence

BPC-157 has not been shown to help joint, tendon or back pain in people. The only human musculoskeletal study is a Florida clinic’s look back at 16 knee-pain patients, with no control group and no standard measure of improvement.^[1][4] There is no human study of BPC-157 for tendon injuries, back pain or any other joint.^[2] The case for it rests on rat studies, where it sped the healing of cut tendons and ligaments.^[6][8] FDA did not evaluate it for tendonitis because the nomination lacked enough information, and it found no clinical studies in that use.^[13] BPC-157 is not FDA-approved for any condition and is banned in sport.^[16]

The evidence by body part

Knee pain: the one human study

The study most often quoted for BPC-157 and knees is a 2021 retrospective review from the Institute for Hormonal Balance in Orlando, Florida. Researchers went through a year of charts, from 2019 to 2020, of patients who had had a peptide injected into the knee, most of them six months to a year earlier. They reached 16 of 17 patients by phone and asked them to rate their pain before the injection, how long relief lasted and how much it helped.^[1]

Of the 12 patients given BPC-157 alone, 11 (91.6%) said their knee pain improved significantly. Of the four given BPC-157 with thymosin beta-4, three improved.^[1] A later systematic review read the same paper as showing that 7 of the 12 reported relief lasting more than six months.^[3] The paper’s title describes multiple types of knee pain, and its introduction lists osteoarthritis, meniscus tears, tendinosis and ligament injuries among the common causes.^[1]

Several things limit what this can show:

• No comparison group. Nobody received a placebo injection or standard care, so natural recovery, the placebo effect and other treatments cannot be ruled out.
• No standard measure. The authors write that no specific tools were used to measure improvement in function, quality of life, stiffness or daily activities.^[1]
• Memory, months later. Patients were asked by phone to recall their pain from before an injection given up to a year earlier.^[1]
• Injection into the joint. The route was a single clinic’s injection into the knee. The HHS policy covers injections under the skin or into muscle, oral products and topical products instead,^[14] and FDA found no human absorption data for any of those routes.^[13]

Orthopedic surgeons reviewing the field in 2026 described this as the whole of the human musculoskeletal evidence: one small retrospective case series without validated outcome measures.^[4] A systematic review the same year rated the certainty of all human BPC-157 evidence as very low.^[2] What the knee study gave and how often is set out in BPC-157 dosage in the studies.

Tendons and ligaments: strong results, all in rats

Most of the reason BPC-157 is sold for tendon injuries comes from rodent studies. In a 2003 study, rats had the Achilles tendon cut just above the heel and received BPC-157 or saline by injection into the abdomen each day. The BPC-157 rats had stronger tendons on load testing, walked better and showed fuller tendon repair by day 14.^[6] Later work by some of the same authors reported faster tendon-to-bone healing after the Achilles was detached from the heel bone.^[7] In the knee’s medial collateral ligament, cut surgically in rats and followed for 90 days, BPC-157 improved healing on function, strength and tissue tests, whether it was injected, added to drinking water or rubbed on as a cream.^[8] In cultured tendon cells, it sped the outgrowth of cells from tendon tissue and their migration, without making them divide faster.^[9]

A systematic review counted 35 preclinical studies against one clinical study, and found that in animals BPC-157 improved function, structure and strength after muscle, tendon, ligament and bone injuries.^[3] A 2026 sports-medicine review found that two-thirds of the published work on popular recovery peptides was in animals.^[12] The results are not uniform: in a 2026 rat study that compared BPC-157 with TB-500 after Achilles repair, only the TB-500 group had significantly stronger tendons than untreated rats, and BPC-157’s tissue scores improved without reaching significance.^[10] That study is covered in BPC-157 vs TB-500.

These rat studies cut or detached healthy tendons and ligaments surgically and followed the animals for two weeks to three months.^[6][8][10] No study has tested whether the results carry over to people with any kind of tendon or ligament problem.^[2][4]

Back pain

There is no human study of BPC-157 for back pain, disc problems or sciatica. The 2026 systematic review found only three human studies of BPC-157 for any use, and none involved the spine.^[2] The closest animal work is in rats with experimental spinal cord injury, a different condition from ordinary back pain.^[11] Claims that BPC-157 heals discs or relieves chronic back pain have no published human or direct animal evidence behind them.

What BPC-157 is said to be good for, and what the evidence supports

Reviewers describe BPC-157 as acting on blood vessel growth, nitric oxide and cell-signaling pathways that could, in theory, help poorly supplied tissues such as tendons heal.^[5] That theory is the basis for the claims. In people, the published record is three small studies with 30 participants in all: the knee report, an interstitial cystitis study and a two-person IV safety study.^[2] The orthopedic reviews reach the same conclusion: BPC-157 is investigational, controlled human trials are missing, and it should not be used outside regulated trials.^[2][4][5]

The pathways that make BPC-157 interesting for healing are also why reviewers ask for long-term safety data. Its effects on new blood vessel growth have not been studied over years in people, and dosing, absorption and long-term safety data are lacking.^[4][5] Product quality is a separate risk: reviewers flag identity, purity, concentration, sterility and manufacturing consistency as open questions for peptides sold online.^[4]

Regulatory status for this use

When BPC-157 was nominated for the 503A compounding list, tendonitis was one of the proposed uses. FDA did not evaluate it, because the nomination did not include enough information, and FDA found no clinical studies of BPC-157 in people with tendonitis.^[13] FDA’s safety-risk page lists BPC-157 among withdrawn nominations and says the agency lacks the information to know whether it would harm people.^[15]

Since October 28, 2026, HHS has said it does not intend to take enforcement action against 503A pharmacies that compound BPC-157 acetate as a subcutaneous or intramuscular injection, an oral product or a topical product, under strict conditions including a prescription for a named patient and a single active ingredient.^[14] Injection into a joint is not among the listed routes. The policy is not an approval and does not cover research-use-only vials.^[14] The World Anti-Doping Agency names BPC-157 in section S0 and bans it at all times.^[16] To check the current status of BPC-157 or any other peptide, use our peptide status checker, and for the other peptides sold for recovery and muscle, see peptides for muscle growth.